Skip to content

Zymeworks ZYME Exchangeable stock, shares issued (in shares)

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.79B+125%

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept zyme:ExchangeableSharesIssued.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Zymeworks's exchangeable stock, shares issued (in shares)?
Zymeworks (ZYME) reported exchangeable stock, shares issued (in shares) of 550.9K in Q1 2026.
How has Zymeworks's exchangeable stock, shares issued (in shares) changed year-over-year?
Zymeworks's exchangeable stock, shares issued (in shares) decreased by 3.3% year-over-year, from 569.9K to 550.9K.
What is the long-term trend for Zymeworks's exchangeable stock, shares issued (in shares)?
Over 3 years (2022 to 2025), Zymeworks's exchangeable stock, shares issued (in shares) has grown at a -27.0% compound annual growth rate (CAGR), from 1.4M to 553.2K.